Edward G. Neilan from NORD discusses critical efforts to speed up therapy development for rare diseases lacking treatments ...

Dynamic clinical pathways are essential to keep pace with rapid advancements in oncology treatments and FDA approvals. Inclusive participation and effective communication are vital for pathway ...

When this is done well, biomarkers accelerate decision-making, reduce uncertainty, and ultimately bring improved therapies to patients faster. When this is done poorly, however, biomarkers can add ...

Company Advances to Active Clinical Execution, Supporting Potential Accelerated Path Toward Regulatory Authorization ATLANTA, ...

Ryan Haumschild, PharmD, MS, MBA, drives an expert discussion focused on challenges associated with clinical pathway utilization in treating patients with HCC. The panel discussion focused on the ...

Expanding the Multidisciplinary Team in Prediagnostic Care of Lung Cancer: How Else Can We Improve Time to Targeted Treatment in Metastatic Non–Small-Cell Lung Cancer? In the article that accompanies ...

Island Pharmaceuticals’ March quarterly update highlights considerable progress advancing the clinical development pathway ...

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study) Receipt of previous ...

Peer-reviewed study in Cell Reports Medicine demonstrates that N17350 delivers selective, immune-activating tumor killing across solid tumor types N17350 targets a cancer vulnerability, via the ELANE ...